

Medical College of Wisconsin presents

Strategies to increase fetal hemoglobin production in patients with Sickle Cell Anemia or Beta-thalassemia using lentivirus-mediated gene delivery

PEDIATRIC HEMATOLOGY/ONCOLOGY/BMT

JOIN US!

Monday, September 17, 2018
10:00-11:00 am

Location: MACC Fund Research
Center, Room 3075

Presented by: Andrew Wilber, PhD

Associate Professor and Director, Public Health Laboratory
Sciences Program
Department of Medical Microbiology, Immunology and Cell Biology
Southern Illinois University School of Medicine



Dr. Wilber has 15 years of experience in the field of gene and cell therapy with expertise in non-viral and viral gene delivery methods. His research program is focused on development of strategies to increase fetal hemoglobin (HbF) production in children or adults with sickle cell disease or severe β -thalassemia following lentiviral vector-mediated gene transfer into the patient's own hematopoietic stem/progenitor cells (HSPC; CD34+ cells). His published works demonstrated that potentially therapeutic levels of HbF could be achieved following delivery of (i) an exogenous γ -globin gene, (ii) an artificial transcriptional activator designed to induce the endogenous γ -globin genes and (iii) shRNAs targeting the γ -globin gene repressor protein BCL11A.

Hosted by:

Jeffrey A. Medin, PhD
MACC Fund Professor, Departments of Pediatrics and Biochemistry
Vice Chair of Research Innovation, Department of Pediatrics
Research Director, Division of Pediatric Hematology/Oncology/BMT
Director GMP Vector Lab